<DOC>
	<DOCNO>NCT02919605</DOCNO>
	<brief_summary>Introduction : Up present , study pentamidine Americas ; consensus regard dose use . Objectives : To evaluate use pentamidine single dose , double triplo treatment cutaneous leishmaniasis . Methods : Clinical trial phase II pilot study 159 patient . Pentamidine use dose 7 mg/kg , three arm : single dose , double dose triple dose . They also assess safety adverse effect . The sic review one , two six month end treatment .</brief_summary>
	<brief_title>Efficacy Safety Pentamidine ( 7mg/kg ) Patients With Cutaneous Leishmaniasis Caused L. Guyanensis</brief_title>
	<detailed_description>This phase II pilot study comprise 159 patient . The sample size calculate study use test difference proportion consider alpha beta error . With estimate cure ratio 80 % group 3 Pentamidine application 7 mg / kg group pentamidine dose 7 mg / kg 58.1 % cure rate , significance level 95 % 80 % test power . Inclusive criterion : Patients sex , age 16 64 , six lesion three month evolution , refer outpatient clinic FMT-HVD agree sign inform consent . CL diagnose positive direct smear ( Giemsa ) specimen obtain border lesion . Exclusion criterion : Patients &gt; three-fold increase upper normal value asparate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) phosphatase alkaline ( ALKP ) ; &gt; 1.5 fold increase upper normal value serum creatinine urea ; glycemia &gt; 110 mg/dl ; evidence severe cardiac , hepatic , renal pulmonary disorder ; severe malnutrition ; active uncontrolled condition tuberculosis , malignancy , malaria , leprosy , HIV , systemic mycoses ( histoplasmosis , paracoccidioidomycosis ) infectious disease ; pregnancy breast feeding ; patient unable understand inform consent , unwilling sign unable comply study protocol . Clinical laboratory workup : Full body skin examination perform . Ulcerated lesion measure pictured treatment . Follow-up measurement picture also take one week , one , two six month treatment . Species identification make polymerase chain reaction ( PCR ) describe elsewhere . Two month treatment , additional smear obtain lesion completely heal and/or show increase , least , 50 % original dimension . Other laboratory exam include complete blood count , sugar , AST , ALT , urea , creatinine amylase blood level , stool parasite examination , routine urine examination rapid test HIV . Drug administration : PI ( 300mg ) dilute 5 ml saline solution single IM injection ( 7 mg/kg ) administer outpatient unit FMT-HVD . Patients give carbohydrate enriched meal treatment prevent hypoglycemia keep rest close clinical observation one hour medication . Rescue treatment IV injection antimonials ( 15 mg/kg every 20 day ) prescribe fail improve . Therapeutic failure define persistence clinical sign ( onset new lesion , &gt; 50 % increase size preexist lesion ) laboratory finding ( positive smear ) two month treatment anytime follow-up period . Adverse effect classify mild ( drug-related , well tolerate , need prescription symptomatic relief ) ; moderate ( drug-related , symptomatic prescription require ) severe ( clinically detectable impairment renal , hepatic cardiac function ) .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Cutaneous</mesh_term>
	<mesh_term>Pentamidine</mesh_term>
	<criteria>Newly diagnose cutaneous leishmaniasis ( untreated ) localize lesion ( without maximum 6 injury ) Direct Examination positive : amastigotes display tissue sample ; Age : 1664 year ; Sex : male female patient eligible ; Disease Clinical Evolution longer 3 month . AST &gt; 3 time upper limit normal ; ALT &gt; 3 time upper limit normal ; Alkaline phosphatase &gt; 3 time upper limit normal ; Serum creatinine urea &gt; 1.5 time upper limit normality ; Blood glucose 110 mg / dl ; Evidence serious underlie disease ( heart , kidney , liver lung ) ; protein / caloric severe malnutrition ; Any uncompensated uncontrolled condition like active tuberculosis , malignant disease , severe malaria , HIV , leprosy , systemic fungal disease ( histoplasmosis , paracoccidioidomycosis ) infectious disease ; Pregnant woman breastfeed ; Lack ability willingness provide inform consent ( patient / parent / legal representative ) ; lack availability visit comply study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Cutaneous Leishmaniasis</keyword>
	<keyword>pentamidine isothionate</keyword>
	<keyword>treatment</keyword>
</DOC>